The Central Bureau of Investigation (CBI) has no input on fugitive businessmen Nitin Sandesara's whereabouts, from the United Arab Emirates (UAE) or Nigeria, confirmed a CBI source.
Sandesara, director of a Gujarat-based pharma company Sterling Biotech, is wanted in a Rs 5,000 crore bank fraud case.
The businessman and his brother Chetan Sandesara fled from the country last year along with family members before the CBI could register an FIR against them, for allegedly defrauding a consortium of state-owned banks.
Following the FIR several movable and immovable properties of the Sandesara brothers were attached under the provisions of the Prevention of Money Laundering Act (PMLA), 2002.
During the investigation, the Enforcement Directorate found that several companies promoted by the Sandesara brothers had fraudulently obtained credit facilities of more than Rs 5000 Crores from various banks, which subsequently turned into Non-Performing Assets (NPAs).
The loans were sanctioned by a consortium of banks led by Andhra Bank, UCO Bank, State Bank of India, Allahabad Bank and Bank of India. The probe further revealed that the promoters set up more than 300 shell and benami companies in India and abroad to divert and misuse loan funds, manipulate balance sheets and fudging other documents to inflate turnovers and insider shares trading.
The Sandesaras reportedly controlled these shell and benami companies through dummy directors, who were shown as employees of various companies of the Sterling Group.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
